Li-Fraumeni syndrome is strongly associated with an increased risk of developing various cancers, most notably breast cancer. Carrying TP53 mutations in the context of Li-Fraumeni syndrome significantly heightens this risk. Studies show that women with Li-Fraumeni syndrome and TP53 mutations have as high as a 90% lifetime risk of developing breast cancer. These TP53 mutations are commonly screened for during genetic testing as part of the syndrome's diagnosis and management plan. Understanding the relationship between Li-Fraumeni syndrome and breast cancer is crucial for targeted surveillance and preventive measures, particularly for carriers of TP53 mutations. Therefore, if you have a family history suggestive of Li-Fraumeni syndrome, consulting a genetic counselor for TP53 mutation testing is highly recommended. This information is especially critical for women who are considering prophylactic mastectomy as an option to mitigate the risk of breast cancer. Overall, the coexistence of Li-Fraumeni syndrome and TP53 mutations necessitates a more aggressive approach to cancer screening and prevention.

свернуть